Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.8 CAD -3.74% Market Closed
Market Cap: 146.9m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Change in Working Capital
-CA$387.9k
CAGR 3-Years
N/A
CAGR 5-Years
43%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Change in Working Capital
-CA$3.6m
CAGR 3-Years
N/A
CAGR 5-Years
67%
CAGR 10-Years
-15%
Sundial Growers Inc
NASDAQ:SNDL
Change in Working Capital
-CA$19.3m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Change in Working Capital
$11.2m
CAGR 3-Years
113%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Change in Working Capital
-$7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-68%
C
Curaleaf Holdings Inc
CNSX:CURA
Change in Working Capital
$133.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
146.9m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Change in Working Capital?
Change in Working Capital
-387.9k CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Change in Working Capital amounts to -387.9k CAD.

What is Cardiol Therapeutics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
43%

Over the last year, the Change in Working Capital growth was -177%.

Back to Top